Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma: a Single-arm, Open-label Clinical Study
Latest Information Update: 15 Apr 2022
At a glance
- Drugs Anti CD30 chimeric antigen receptor T cell therapy Wuhan Bio Raid Biotechnology (Primary) ; Camrelizumab (Primary)
- Indications Lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Apr 2022 New trial record